Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 11, 2021

SELL
$76.15 - $111.94 $31,221 - $45,895
-410 Closed
0 $0
Q4 2020

Jan 19, 2021

SELL
$96.85 - $148.25 $3.03 Million - $4.65 Million
-31,333 Reduced 98.71%
410 $41,000
Q3 2020

Oct 20, 2020

SELL
$122.47 - $213.56 $381,616 - $665,452
-3,116 Reduced 8.94%
31,743 $4.5 Million
Q2 2020

Jul 30, 2020

SELL
$185.52 - $231.25 $950,604 - $1.18 Million
-5,124 Reduced 12.82%
34,859 $6.88 Million
Q1 2020

Apr 17, 2020

SELL
$143.0 - $274.03 $3.35 Million - $6.43 Million
-23,461 Reduced 36.98%
39,983 $7.83 Million
Q4 2019

Jan 16, 2020

SELL
$146.12 - $215.82 $1.17 Million - $1.73 Million
-7,998 Reduced 11.2%
63,444 $13.1 Million
Q3 2019

Oct 16, 2019

SELL
$130.44 - $187.64 $613,850 - $883,033
-4,706 Reduced 6.18%
71,442 $10.9 Million
Q2 2019

Jul 18, 2019

SELL
$111.45 - $128.93 $975,410 - $1.13 Million
-8,752 Reduced 10.31%
76,148 $0
Q1 2019

Apr 12, 2019

SELL
$89.61 - $117.78 $157,534 - $207,057
-1,758 Reduced 2.03%
84,900 $0
Q4 2018

Jan 17, 2019

SELL
$87.81 - $110.65 $49,963 - $62,959
-569 Reduced 0.65%
86,658 $7.95 Million
Q3 2018

Oct 18, 2018

SELL
$90.63 - $120.22 $1.85 Million - $2.46 Million
-20,448 Reduced 18.99%
87,227 $0
Q2 2018

Jul 12, 2018

BUY
$88.4 - $105.34 $489,647 - $583,478
5,539 Added 5.42%
107,675 $0
Q1 2018

Apr 16, 2018

SELL
$94.51 - $120.23 $1.42 Million - $1.81 Million
-15,075 Reduced 12.86%
102,136 $0
Q4 2017

Jan 24, 2018

BUY
$84.48 - $104.02 $896,924 - $1.1 Million
10,617 Added 9.96%
117,211 $0
Q3 2017

Oct 25, 2017

BUY
$73.17 - $103.47 $7.8 Million - $11 Million
106,594
106,594 $0

Others Institutions Holding GLPG

About GALAPAGOS NV


  • Ticker GLPG
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,835,500
  • Market Cap $1.76B
  • Description
  • Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...
More about GLPG
Track This Portfolio

Track Peregrine Capital Management LLC Portfolio

Follow Peregrine Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peregrine Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peregrine Capital Management LLC with notifications on news.